Royalty Report: Drugs, Therapeutic, Cancer – Collection: 243435

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Cancer
  • Disease
  • Diagnostic
  • Delivery
  • Autoimmune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243435

License Grant
The University grants an exclusive worldwide license under the patent rights and know-how to make, have made, use, import, offer to sell, sell, offer to provide and provide Licensed Products. Such license is worldwide.  The University grants an exclusive option to obtain an exclusive, worldwide license to all new optioned inventions.
License Property
The property is referred to as Licensors 1101 Invention or the 1215 Invention.  The patented invention relates to Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA.  The inventions are detailed in patent applications #08/517,373, #08/700,035, #96/13,457 and also #08/640,444, and continuation applications.
Field of Use
The field shall mean all uses of the know-how and patent rights, cell lines, substances and material produced by cell lines and included in Patent Rights, specifically including, without limitation, research and development, diagnosis, prevention, therapy, and monitoring of all human and animal diseases or disorders, including  autoimmune diseases or disorders, infectious diseases or cancer in humans or animals.

IPSCIO Record ID: 253909

License Grant
With the amendment,  the Institute, an university, grants an exclusive license under the Nanocell Patent rights to develop, make, have made, use, sell, offer to sell, lease and import Licensed Products in the Field in the Territory and to develop and perform Licensed Processes in the Field in the Territory; and, an exclusive license under the Platinum Product Patent Rights to develop, make, have made, use, sell, offer to sell, lease and import Licensed Products solely in the Nanocell Field in the Territory.

The Institute grants a first option to add improvements to the Nanocell Patent Rights, only in the Field, for six months after Licensee has been notified of the existence of each such improvement.

License Property
The patents cover Nanocell Dmg Delivery System, and, Nanocells For Diagnosis And Treatment Of Diseases And Disorders, and, Tailored Nanocells For The Treatment And Prevention Of Diseases and Disorders.

Institute  is the owner of certain PATENT RIGHTS relating invention disclosures and patent applications relating to Institute Case No. 100l7'A Novel Method for the Treatment of Cancer Using Particles and Institute Case 11463 'Use of Nanocells for Imagine Tumors'.

Field of Use
The Nanocell field shall mean the treatment of human and veterinary disease using a pharmaceutical composition.

IPSCIO Record ID: 203285

License Grant
Licensor grants an exclusive, worldwide, non-transferable, license, with the right to sublicense, under the Licensor Patent Rights and Know-How to make, use, including in activities directed at the research and Development of Licensed Compounds, have made, sell, have sold, offer to sell, export, import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.

License Property
MS564929 Toxicology Studies means the two (2) toxicology reports due n the IND covering the BMS compound designated BMS564929, specifically the 6 onth oral toxicology studies in rats and dogs.

6,670,386 – Bicyclic modulators of androgen receptor function

The licensed compounds and patents relate to controlling various diseases and cancers.

Field of Use
The Field means the diagnosis, prevention, treatment or control of any human or animal disease, disorder or condition, excluding the prevention, treatment or control of any human or animal hyperproliferative disease, disorder or condition. For purposes of clarity, hyperproliferative diseases, disorders and conditions are those diseases, disorders or conditions which are characterized by an abnormal increase in the proliferation or accumulation of cells and include conditions such as cancers and benign hyperplasia, but not diseases, disorders or conditions incident to an abnormal increase in the proliferation or accumulation of cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.